U.S. government awards $2.1B to Sanofi-GSK coronavirus vaccine

Sanofi and GlaxoSmithKline will receive up to $2.1 billion from the U.S. government to further develop their coronavirus vaccine and provide Americans with 100 million doses.

The U.S. has the option to purchase another 500 million doses of the vaccine if it proves safe and effective, the companies said Friday.

This is the largest award yet to a vaccine developer from the government’s Operation Warp Speed vaccine and drug accelerator.